Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate

February 24, 2026 | News

See attached press release

Related Posts

Centauri Theraputics Main Logo

Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infections

March 10, 2026 | News
Read More about Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infections

Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

July 29, 2025 | News Updates
Read More about Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

Centauri Therapeutics appoints Dr. Debra Barker as Chief Medical Officer

July 8, 2025 | News Updates
Read More about Centauri Therapeutics appoints Dr. Debra Barker as Chief Medical Officer